抗艾药品绥美凯上市了吗

Are anti-AIDS drugs on the market?

Suimeike (dolutegravir tablets, Inbec) was initially approved for marketing in the United States in 2014. It is currently the only three-in-one compound drug containing dolutegravir (DTG). Suimeikai (Dolutea Paramid Tablets, Inbec) has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.

On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation Suimeike (dolute abalamib tablets, Inbec) was officially launched in mainland China. This is the best-selling AIDS drug in the world in the past five years.

TRIUMEQ (dolutegravir, abacavir, or lamivudine) is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine can be used. In these cases, physicians should refer to the respective product information for these medicines. If the patient misses a dose of TRIUMEQ (TRIUMEQ) and there are more than 4 hours before the next dose, he should take TRIUMEQ as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

Patients treated with TRIUMEQ should be aware that patients with pre-existing liver dysfunction, including patients with chronic active hepatitis, may develop liver function abnormalities with increased frequency during combined antiretroviral therapy and should be monitored according to standard protocols. If in these patients there is evidence of worsening liver disease, withholding or discontinuing treatment should be considered.

(Dolutea, Inbec) is indicated for use in adults and adolescents over 12 years of age (weight at least 40 kg) infected with the human immunodeficiency virus (HIV) (in HIV-infected patients, regardless of the patient's race, before starting treatment with abacavir-containing products, screening should be Whether the patient carries the HLA-B*5701 allele. If the patient is known to carry the RLA-B*5701 allele, he should not take treatment with products containing abacavir. The treatment effect varies from person to person, and different physiques and medication methods will have an impact on the effectiveness of the drug.

Recommended related hot articles: /newsDetail/80729.html